Posted inStock
UBS revises Coloplast rating to ‘neutral,’sees lower risk
UBS has adjusted its rating on Coloplast (CSE:COLOb) A/S, upgrading the Danish healthcare company to “neutral” from “sell.” This revision reflects changes in market dynamics and a reassessment of risk…